Trianglecemacabtagene ansegedleucel (NCT06500273)
cemacabtagene ansegedleucel trial for Large B-cell Lymphoma (NCT06500273). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with selected large B-cell lymphomas in complete remission, or a partial remission suitable for observation, after one initial treatment course. The study's residual-disease test must remain positive. Transformed lymphomas and prior CD19-targeted therapy are excluded.
The idea: randomly compare observation with cema-cel, donor CAR-T cells that target CD19. Fludarabine and cyclophosphamide reduce lymphocytes before cell treatment. Researchers test whether this consolidation improves event-free survival and assess safety.
This phase 2 study plans 250 patients. Allogene Therapeutics sponsors sixty-two recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.